Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 10:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 2,549 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Pharmacokinetic study Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Danavorexton in Anesthetized Adults

NCT05025397
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Danavorexton, Danavorexton Placebo, Propofol, Sevoflurane
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Oct 18, 2026, 10:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic Study of CVX-096 (PF-04856883) in Healthy Volunteers

NCT01637285
View directory record Official record
Conditions
Healthy
Interventions
PF-04856883
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 31, 2015 · Synced Oct 18, 2026, 10:05 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Comparison of Cadazolid Versus Vancomycin in Children With Clostridium Difficile-associated Diarrhea (CDAD)

NCT03105479
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Cadazolid, Vancomycin capsule, Vancomycin solution
Drug
Lead sponsor
Actelion
Industry
Eligibility
Up to 18 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
5
States / cities
Idaho Falls, Idaho • Chicago, Illinois • Shreveport, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2025 · Synced Oct 18, 2026, 10:05 AM EDT
Completed Phase 1 Interventional

Pharmacokinetic (PK) Study of Homoharringtonine (Omacetaxine Mepesuccinate) Administered Subcutaneously to Patients With Advanced Solid and Hematologic Tumors

NCT00675350
View directory record Official record
Conditions
Hematologic Tumors
Interventions
Omacetaxine
Drug
Lead sponsor
ChemGenex Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 12, 2014 · Synced Oct 18, 2026, 10:05 AM EDT
Not listed Phase 3 Interventional

Safety, Efficacy and Pharmacokinetics of GreenGene™ F to Previously Treated Patients With Severe Hemophilia A

NCT01619046
View directory record Official record
Conditions
Hemophilia A
Interventions
GreenGene™ F and an approved recombinant Factor VIII product, GreenGene™ F
Biological
Lead sponsor
Green Cross Corporation
Industry
Eligibility
12 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
10
States / cities
Little Rock, Arkansas • Los Angeles, California • Torrance, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2014 · Synced Oct 18, 2026, 10:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Impact of Weekly Administration of Rifapentine and Isoniazid on Steady State Pharmacokinetics of Tenofovir Alafenamide in Healthy Volunteers (YODA)

NCT03510468
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Tenofovir alafenamide, Rifapentine, Isoniazid (INH), Pyridoxine
Drug · Dietary Supplement
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 13, 2024 · Synced Oct 18, 2026, 10:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Safety Study Evaluating N6022 in Multiple-Ascending Doses in Healthy Subjects

NCT01339897
View directory record Official record
Conditions
Healthy
Interventions
5 mg/N6022, Placebo, 10mg/N6022, 20mg/N6022
Drug
Lead sponsor
Nivalis Therapeutics, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 19, 2015 · Synced Oct 18, 2026, 10:05 AM EDT
Completed Phase 2 Interventional Results available

Azacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML)

NCT00813124
View directory record Official record
Conditions
Stem Cell Transplantation, Leukemia
Interventions
Fludarabine, Busulfan, Thymoglobulin, Azacitidine, Stem Cell Transplant
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2021 · Synced Oct 18, 2026, 10:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic and Safety Study of Cenicriviroc and HMG-CoA Reductase Inhibitors, Caffeine and Digoxin

NCT02685462
View directory record Official record
Conditions
Healthy
Interventions
Rosuvastatin, Atorvastatin, Simvastatin, Digoxin, Caffeine
Drug
Lead sponsor
Tobira Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 24, 2017 · Synced Oct 18, 2026, 10:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I One-month Safety, PK, PD, and Acceptability Study of IVR Releasing TFV and LNG or TFV Alone

NCT02235662
View directory record Official record
Conditions
HIV, Contraception
Interventions
TFV IVR, TFV/LNG IVR, Placebo IVR
Drug · Other
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 11, 2016 · Synced Oct 18, 2026, 10:05 AM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients

NCT03359850
View directory record Official record
Conditions
Ovarian Neoplasms, Neoplasms, Solid Tumor, Hepatic Impairment
Interventions
Niraparib
Drug
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
5
States / cities
Los Angeles, California • Newport Beach, California • Aurora, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated May 28, 2021 · Synced Oct 18, 2026, 10:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

SAD Study to Evaluate Safety, Tolerability, and Pharmacokinetic Profile of AMN1126 in Healthy Post-Menopausal Females

NCT06467201
View directory record Official record
Conditions
Healthy Postmenopausal Women
Interventions
KSHN001126 150mg, KSHN001126 300mg, KSHN001126 600mg
Drug
Lead sponsor
Amneal Pharmaceuticals, LLC
Industry
Eligibility
45 Years to 60 Years · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 18, 2026, 10:05 AM EDT
Terminated Phase 2 Interventional Results available

A Two-week Open-label Pharmacodynamic and Pharmacokinetic Study of Multiple Doses of a Darifenacin Liquid Oral Suspension in Children (2 - 15 Years) With Neurogenic Detrusor Overactivity

NCT00712322
View directory record Official record
Conditions
Neurogenic Detrusor Overactivity
Interventions
Darifenacin
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
2 Years to 15 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
9
States / cities
San Diego, California • Boston, Massachusetts • Detroit, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2022 · Synced Oct 18, 2026, 10:05 AM EDT
Completed Phase 1 Interventional

Open-label Study of DS-8273a to Assess Its Safety and Tolerability, and Assess Its Pharmacokinetic and Pharmacodynamic Properties in Subjects With Advanced Solid Tumors or Lymphomas

NCT02076451
View directory record Official record
Conditions
Advanced Solid Tumor, Lymphoma
Interventions
DS-8273a
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 12, 2019 · Synced Oct 18, 2026, 10:05 AM EDT
Recruiting Phase 3 Interventional

A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

NCT06747351
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Interventions
TAK-881, HYQVIA, SC Investigational Needle Sets
Biological · Device
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
16
States / cities
Scottsdale, Arizona • Palo Alto, California • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 18, 2026, 10:05 AM EDT
Terminated Phase 1 Interventional

Safety Study of AMG 557 in Subjects With Subacute Cutaneous Lupus Erythematosus

NCT01389895
View directory record Official record
Conditions
Cutaneous Lupus, Lupus
Interventions
AMG 557, AMG 557 Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
7
States / cities
Birmingham, Alabama • Ann Arbor, Michigan • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2014 · Synced Oct 18, 2026, 10:05 AM EDT
Active, not recruiting Phase 1 Interventional

Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Newborns Exposed to HIV

NCT07055451
View directory record Official record
Conditions
HIV-1-infection
Interventions
B/F/TAF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
Up to 120 Hours
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
3
States / cities
Los Angeles, California • Atlanta, Georgia • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 18, 2026, 10:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Study of Pitavastatin and Ritonavir-Boosted Darunavir or Efavirenz

NCT01695954
View directory record Official record
Conditions
Hyperlipidemia, HIV
Interventions
Pitavastatin, Darunavir, Ritonavir, Efavirenz
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 60 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Oct 18, 2026, 10:05 AM EDT
Completed Phase 1 Interventional

A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07)

NCT05524545
View directory record Official record
Conditions
Bladder Cancer, Urothelial Carcinoma
Interventions
Evorpacept, Enfortumab Vedotin
Drug
Lead sponsor
ALX Oncology Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
8
States / cities
Tampa, Florida • Boston, Massachusetts • New York, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2025 · Synced Oct 18, 2026, 10:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Pharmacokinetic and Safety Profile of Androxal in Male Subjects With Impaired Renal Function

NCT01923857
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
Androxal 25 mg
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 80 Years · Male only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
2
States / cities
Miami, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 11, 2014 · Synced Oct 18, 2026, 10:05 AM EDT
Completed Phase 2 Interventional

Using Drug Levels and Drug Resistance Testing to Select Effective Anti-HIV Drug Combinations in Patients With Drug-resistant HIV

NCT00027339
View directory record Official record
Conditions
HIV Infections
Interventions
lopinavir/ritonavir, indinavir sulfate, tenofovir disoproxil fumarate, ritonavir, fosamprenavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
13
States / cities
Los Angeles, California • Palo Alto, California • Sacramento, California + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 18, 2026, 10:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Colchicine on the Pharmacokinetic Profile of LC350189 in Healthy Aldults.

NCT03927677
View directory record Official record
Conditions
Gout, Hyperuricemia
Interventions
Xanthine Oxidase Inhibitor
Drug
Lead sponsor
LG Chem
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 26, 2020 · Synced Oct 18, 2026, 10:05 AM EDT
Not listed Phase 4 Interventional

Impact of Bariatric Surgery on Pharmacokinetic Study of Simvastatin and Carvedilol

NCT04049786
View directory record Official record
Conditions
Obesity, Bariatric Surgery, Roux-en Y Gastric Bypass
Interventions
Digestive biopsy, Carvedilol 25mg, Serial blood sampling for PK analysis, Metoprolol 100 mg for CYP2D6 phenotyping, Simvastatin 40mg, Midazolam 2 mg for CYP3A4 phenotyping, Genotyping
Procedure · Drug · Other
Lead sponsor
Natalia Valadares de Moraes
Other
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 8, 2022 · Synced Oct 18, 2026, 10:05 AM EDT
Completed Phase 1 Interventional

Chemotherapy in Treating Patients With Advanced Solid Tumors

NCT00003709
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
carbendazim
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
2
States / cities
Fort Sam Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 9, 2012 · Synced Oct 18, 2026, 10:05 AM EDT